INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata

Background: The INTREPID study showed improved health status response and lung function in chronic obstructive pulmonary disease (COPD) usual care with single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs multiple-inhaler triple therapy (MITT; inhaled corticosteroid+long-acting muscarinic antagonist+long-acting β2-agonist [ICS+LAMA+LABA]). Aim: Evaluate INTREPID outcomes by prior medication strata. Methods: The open-label, phase IV INTREPID study included 3092 intent-to-treat (ITT) COPD patients who received non-ELLIPTA maintenance therapy for ≥16 weeks, had COPD Assessment Test (CAT) score ≥10 and ≥1 moderate/severe exacerbation in prior 3 years, randomised to FF/UMEC/VI 100/62.5/25µg via ELLIPTA or clinician choice of ICS+LAMA+LABA MITT in non-ELLIPTA devices for 24 weeks. Outcomes were analysed by prior medication strata (ICS+LAMA+LABA, ICS+LABA, LAMA+LABA). Results: Odds of CAT response and lung function improvement at Week 24 were statistically significantly greater for FF/UMEC/VI vs MITT in ICS+LAMA+LABA and ICS+LABA strata, and similar in LAMA+LABA stratum (Table). Adverse event incidence was broadly similar by prior medication strata. Conclusions: In usual care, FF/UMEC/VI significantly improved health status response and lung function vs MITT in patients on prior ICS-containing therapy. Method: GSK (206854/NCT03467425).